Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study

A. Zeleniuch-Jacquotte, R. E. Shore, K. L. Koenig, A. Akhmedkhanov, Y. Afanasyeva, I. Kato, Mimi Kim, S. Rinaldi, R. Kaaks, P. Toniolo

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

We assessed the association of sex hormone levels with breast cancer risk in a case-control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2. 49 (1.47-4.21), Ptrend=0.003 for oestradiol; 3.24 (1.87-5.58), P trend<0.001 for oestrone; 2.37 (1.39-4.04), Ptrend=0. 002 for testosterone; 2.07 (1.28-3.33), Ptrendd<0.001 for androstenedione; 1.74 (1.05-2.89), Ptrend<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31-0.82), P trend<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92-1.26 for testosterone; 1.15, 95% CI=0.95-1.39 for androstenedione and 1.06, 95% CI=0.90-1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalBritish Journal of Cancer
Volume90
Issue number1
DOIs
StatePublished - Jan 12 2004

Fingerprint

Sex Hormone-Binding Globulin
Androgens
Estrogens
Dehydroepiandrosterone Sulfate
Prospective Studies
Breast Neoplasms
Confidence Intervals
Androstenedione
Estrone
Hormones
Testosterone
Gonadal Steroid Hormones
Women's Health
Blood Donors
Case-Control Studies
Estradiol
Neoplasms
Odds Ratio

Keywords

  • Androgen
  • Androstenedione
  • Breast cancer
  • DHEAS
  • Oestradiol
  • Oestrogen
  • Oestrone
  • SHBG
  • Testosterone

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zeleniuch-Jacquotte, A., Shore, R. E., Koenig, K. L., Akhmedkhanov, A., Afanasyeva, Y., Kato, I., ... Toniolo, P. (2004). Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study. British Journal of Cancer, 90(1), 153-159. https://doi.org/10.1038/sj.bjc.6601517

Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer : Long-term results of a prospective study. / Zeleniuch-Jacquotte, A.; Shore, R. E.; Koenig, K. L.; Akhmedkhanov, A.; Afanasyeva, Y.; Kato, I.; Kim, Mimi; Rinaldi, S.; Kaaks, R.; Toniolo, P.

In: British Journal of Cancer, Vol. 90, No. 1, 12.01.2004, p. 153-159.

Research output: Contribution to journalArticle

Zeleniuch-Jacquotte, A, Shore, RE, Koenig, KL, Akhmedkhanov, A, Afanasyeva, Y, Kato, I, Kim, M, Rinaldi, S, Kaaks, R & Toniolo, P 2004, 'Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study', British Journal of Cancer, vol. 90, no. 1, pp. 153-159. https://doi.org/10.1038/sj.bjc.6601517
Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study. British Journal of Cancer. 2004 Jan 12;90(1):153-159. https://doi.org/10.1038/sj.bjc.6601517
Zeleniuch-Jacquotte, A. ; Shore, R. E. ; Koenig, K. L. ; Akhmedkhanov, A. ; Afanasyeva, Y. ; Kato, I. ; Kim, Mimi ; Rinaldi, S. ; Kaaks, R. ; Toniolo, P. / Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer : Long-term results of a prospective study. In: British Journal of Cancer. 2004 ; Vol. 90, No. 1. pp. 153-159.
@article{ccf0b887edd64eccb8e56fc854a435ad,
title = "Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study",
abstract = "We assessed the association of sex hormone levels with breast cancer risk in a case-control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95{\%} confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2. 49 (1.47-4.21), Ptrend=0.003 for oestradiol; 3.24 (1.87-5.58), P trend<0.001 for oestrone; 2.37 (1.39-4.04), Ptrend=0. 002 for testosterone; 2.07 (1.28-3.33), Ptrendd<0.001 for androstenedione; 1.74 (1.05-2.89), Ptrend<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31-0.82), P trend<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95{\%} CI=0.92-1.26 for testosterone; 1.15, 95{\%} CI=0.95-1.39 for androstenedione and 1.06, 95{\%} CI=0.90-1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.",
keywords = "Androgen, Androstenedione, Breast cancer, DHEAS, Oestradiol, Oestrogen, Oestrone, SHBG, Testosterone",
author = "A. Zeleniuch-Jacquotte and Shore, {R. E.} and Koenig, {K. L.} and A. Akhmedkhanov and Y. Afanasyeva and I. Kato and Mimi Kim and S. Rinaldi and R. Kaaks and P. Toniolo",
year = "2004",
month = "1",
day = "12",
doi = "10.1038/sj.bjc.6601517",
language = "English (US)",
volume = "90",
pages = "153--159",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer

T2 - Long-term results of a prospective study

AU - Zeleniuch-Jacquotte, A.

AU - Shore, R. E.

AU - Koenig, K. L.

AU - Akhmedkhanov, A.

AU - Afanasyeva, Y.

AU - Kato, I.

AU - Kim, Mimi

AU - Rinaldi, S.

AU - Kaaks, R.

AU - Toniolo, P.

PY - 2004/1/12

Y1 - 2004/1/12

N2 - We assessed the association of sex hormone levels with breast cancer risk in a case-control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2. 49 (1.47-4.21), Ptrend=0.003 for oestradiol; 3.24 (1.87-5.58), P trend<0.001 for oestrone; 2.37 (1.39-4.04), Ptrend=0. 002 for testosterone; 2.07 (1.28-3.33), Ptrendd<0.001 for androstenedione; 1.74 (1.05-2.89), Ptrend<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31-0.82), P trend<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92-1.26 for testosterone; 1.15, 95% CI=0.95-1.39 for androstenedione and 1.06, 95% CI=0.90-1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.

AB - We assessed the association of sex hormone levels with breast cancer risk in a case-control study nested within the cohort of 7054 New York University (NYU) Women's Health Study participants who were postmenopausal at entry. The study includes 297 cases diagnosed between 6 months and 12.7 years after enrollment and 563 controls. Multivariate odds ratios (ORs) (95% confidence interval (CI)) for breast cancer for the highest quintile of each hormone and sex-hormone binding globulin (SHBG) relative to the lowest were as follows: 2. 49 (1.47-4.21), Ptrend=0.003 for oestradiol; 3.24 (1.87-5.58), P trend<0.001 for oestrone; 2.37 (1.39-4.04), Ptrend=0. 002 for testosterone; 2.07 (1.28-3.33), Ptrendd<0.001 for androstenedione; 1.74 (1.05-2.89), Ptrend<0.001 for dehydroepiandrosterone sulphate (DHEAS); and 0.51 (0.31-0.82), P trend<0.001 for SHBG. Analyses limited to the 191 cases who had donated blood five to 12.7 years prior to diagnosis showed results in the same direction as overall analyses, although the tests for trend did not reach statistical significance for DHEAS and SHBG. The rates of change per year in hormone and SHBG levels, calculated for 95 cases and their matched controls who had given a second blood donation within 5 years of diagnosis, were of small magnitude and overall not different in cases and controls. The association of androgens with risk did not persist after adjustment for oestrone (1.08, 95% CI=0.92-1.26 for testosterone; 1.15, 95% CI=0.95-1.39 for androstenedione and 1.06, 95% CI=0.90-1.26 for DHEAS), the oestrogen most strongly associated with risk in our study. Our results support the hypothesis that the associations of circulating oestrogens with breast cancer risk are more likely due to an effect of circulating hormones on the development of cancer than to elevations induced by the tumour. They also suggest that the contribution of androgens to risk is largely through their role as substrates for oestrogen production.

KW - Androgen

KW - Androstenedione

KW - Breast cancer

KW - DHEAS

KW - Oestradiol

KW - Oestrogen

KW - Oestrone

KW - SHBG

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=10744233063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744233063&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601517

DO - 10.1038/sj.bjc.6601517

M3 - Article

C2 - 14710223

AN - SCOPUS:10744233063

VL - 90

SP - 153

EP - 159

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -